QualityStocksNewsBreaks Archives - Page 685 of 1520

MondayAug 23, 2021 1:35 pm

QualityStocksNewsBreaks – FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) Poised to Improve Ammonia Production Methods at an Affordable, Modular, Commercial Scale

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) is working to commercialize its patent-pending first-of-its-kind carbon-free ammonia (“NH3”) technology as a more efficient alternative to existing efforts. In a June investor presentation, Fuel Positive CEO Ian Clifford noted that the environmental imperative for scalable and economically viable replacements for fossil fuel and other highly polluting materials has never been more important. According to a recent article, Clifford's statement reflected “a rising sense of global urgency for using energy in a sustainable way that doesn't compromise the needs of future generations for the sake of current conveniences — a concern intensified by increasing reports…

MondayAug 23, 2021 1:06 pm

QualityStocksNewsBreaks – Perpetual Industries Inc. (PRPI) Subsidiary’s Upcoming Auctions to Feature Exclusive Collections of Vintage Cars, Motorcycles

Perpetual Industries’ (OTC: PRPI) wholly owned subsidiary Worldwide Auctioneers is preparing to hold two highly distinguishable auctions scheduled for Sept. 4 and Sept. 10-11, 2021. The auctions will feature an impressive gathering of vintage cars offered without reserve and one of the most significant motorcycle collections to come to market. According to a recent article, the Sept. 4 auction “features one of Worldwide Auctioneers’ most exclusive lists of offerings yet, including outstanding prewar automobiles, select muscle cars, American and European sportscars, classics and racers, as well as an exceptional selection of the best automobilia and memorabilia to be found.” The…

MondayAug 23, 2021 12:51 pm

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Featured in Visual Capitalist Article

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, was recently featured as a sponsored content provider on the Visual Capitalist. In the article, part one of a two-part series titled, “The History of Psychedelics (Part 1 of 2),” Tryp delves into the evolution of psychedelics from an ancient antidote “to breakthrough medicine with massive therapeutic potential for a wide range of notoriously hard-to-treat diseases.” “With these strict legal changes around the world, the psychedelics industry became largely inactive. But today, an explosion of unprecedented…

MondayAug 23, 2021 12:18 pm

QualityStocksNewsBreaks – Why Flora Growth Corp. (NASDAQ: FLGC) Is ‘One to Watch’

Flora Growth Corp. (NASDAQ: FLGC), an internationally focused cannabis brand builder, boasts a portfolio that spans several verticals, including pharmaceuticals, textiles, cosmetics, and food and beverage — each with a thoughtful brand designed to resonate with its intended end customer. From Flora Lab SAS and Flora Beauty to KASA Wholefoods and Hemp Textiles & Co., each of its brands prioritizes natural ingredients and value-chain sustainability, consistent with its mission. Though the company is currently organically growing market share for its existing brand portfolio, it is also seeking revenue-generating acquisitions that offer an accretive distribution network to amplify growth. As such,…

MondayAug 23, 2021 10:36 am

QualityStocksNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Files for Registration Testing of Its Multicancer CDA Device

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has filed with China’s National Medical Products Administration (“NMPA”) for registration testing of its class III, multicancer detection medical device; the device, which has been tested and evaluated extensively, features AnPac’s proprietary Cancer Differentiation Analysis Technology (“CDA”). The company has reported that all preclinical trials and tests conducted through July 2021 have produced positive results. Approval of the NMPA application would allow the device to be used to assist in the diagnosis of 11 different types of cancer, including lung, esophageal, gastric, rectal, colon,…

MondayAug 23, 2021 10:07 am

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Receives FDA Clearance for mmRNA Oral Appliance

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has received 510(k) market clearance from the FDA for its modified mandibular repositioning nighttime appliance (“mmRNA”). The device is designed to treat mild-to-moderate OSA in adults; it is also used for treating sleep-disordered breathing and snoring. The FDA approval expands insurance reimbursement potential, including the potential for the device to be covered by Medicare. The FDA approval also opens the door for future government contracts and other commercial payers. According…

MondayAug 23, 2021 9:59 am

QualityStocksNewsBreaks – ISW Holdings Inc. (ISWH) Announces Q2 Financial Performance, Provides Corporate Update

ISW Holdings (OTC: ISWH) (transitioning to “BlockQuarry,” pending name change), a Nevada-based portfolio company with primary commercial-stage operations in cryptocurrency mining, today announced the filing of the company’s financial performance data for the three months ended June 30, 2021. “Our primary mining equipment was not installed and switched on until about two weeks before the end of Q2, so the bulk of the impact will show up in Q3 data in terms of topline numbers,” commented Alonzo Pierce, president and chairman of ISW Holdings. “That said, we have significant equipment now running and just received another large delivery of miners,…

MondayAug 23, 2021 9:26 am

QualityStocksNewsBreaks – TAAT Global Alternatives Inc. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) Receives $1M-Plus Order from UK Distributor

TAAT(TM) Global Alternatives (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) has received an order for two containers of its flagship product, TAAT(TM) tobacco-free, nicotine-free cigarette alternative. The order came from an England-based wholesaler and is valued at approximately C$1,075,000; this is the second order from the wholesaler, which will be the exclusive distributor for TAAT in the United Kingdom and Ireland. The wholesaler had placed an initial order of approximately C$149,000. According to the announcement, the distributor has received a Confirmation of Registration to the Tobacco and Related Products and Regulatory Competent Authority from Public Health England, which provides permission for TAAT to be…

FridayAug 20, 2021 1:17 pm

QualityStocksNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Announces Progress That Tells of the Dawn of Exciting Times

Red White & Bloom Brands’ (CSE: RWB) (OTCQX: RWBYF) CEO Brad Rogers, in a statement contained in the company’s investor deck presentation, observed that multiple deals, “judiciously purchased and diligently structured,” were coming together to create “the most exciting times in the history of the company.” Rogers further noted that the company was focused on building its key assets and growing the bottom line for its shareholders. “Red White & Bloom recently made two announcements that show its progress thus far and perhaps tell of the dawn of the exciting times. On July 22, the company announced its Q4 2020…

FridayAug 20, 2021 12:55 pm

QualityStocksNewsBreaks – Brain Scientific Inc. (BRSF) Tapping into AI, ML Technology to Facilitate Early Diagnosis of Brain Disorders

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, commenced its three-stage development process with the first phase in 2018 that resulted in the creation of the NeuroCap(TM) and NeuroEEG(TM). “The second phase, currently ongoing, is focused on the development of essential cloud-based infrastructure that will be used to transmit data between patients and neurologists. The third and final phase, scheduled for later this year and into 2022 and 2023, will focus on the development of AI and ML processes to increase efficiency, consistency and accuracy of diagnostic analytics provided by the application,” reads a…

Site Search

Company Search

Category: QualityStocksNewsBreaks